https://smallinsight.com/corporate-analysis/hanol-biopharmas-strong-drug-sales-drive-q3-revenue-to-krw-124/ SmallInsight en 2026-10-28T17:27:06.000Z Hanol Biopharma's Strong Drug Sales Drive Q3 Revenue to KRW 1.24 Trillion https://smallinsight.com/stock-news/nationwide-consumer-festival-kicks-off-from-beef-to-electronics/ SmallInsight en 2026-10-28T17:07:19.000Z Nationwide Consumer Festival Kicks Off: From Beef to Electronics, a Week of Deals Starts Friday https://smallinsight.com/corporate-analysis/hd-hyundai-electric-expands-production-riding-high-on-surging/ SmallInsight en 2026-10-28T16:51:27.000Z HD Hyundai Electric Expands Production, Riding High on Surging Orders https://smallinsight.com/market-briefing/kospi-recovers-to-6000-level-net-purchase-by-foreign-investors/ SmallInsight en 2026-10-28T16:32:04.000Z [KRX deadline | October 28] KOSPI recovers to 6000 level... Net purchase by Foreign Investors and institutions of KRW 1.7835 trillion https://smallinsight.com/corporate-analysis/dae-woong-pharmas-enblo-doubles-down-on-appetite-control-showing/ SmallInsight en 2026-10-28T15:55:58.000Z Dae Woong Pharma's 'Enblo' Doubles Down on Appetite Control, Showing Promise for Metabolic Disorders Beyond Diabetes https://smallinsight.com/market-briefing/ai-bears-silenced-by-niks-stellar-performance/ SmallInsight en 2026-10-28T15:18:00.000Z [Seoul Market Wrap] AI Bears Silenced by 'Niks' Stellar Performance https://smallinsight.com/corporate-analysis/gm-joins-hybrid-race-intensifying-suv-battle-with-hyundai-and/ SmallInsight en 2026-10-28T14:15:31.000Z GM Joins Hybrid Race, Intensifying SUV Battle with Hyundai and Kia in the U.S. https://smallinsight.com/stock-news/nvidias-strategic-move-boosting-ai-inference-efficiency-through/ SmallInsight en 2026-10-28T13:57:20.000Z Nvidia's Strategic Move: Boosting AI Inference Efficiency Through Investment and Software https://smallinsight.com/corporate-analysis/sk-hynixs-profits-soar-as-memory-chip-demand-booms-operating/ SmallInsight en 2026-10-28T11:32:04.000Z SK Hynix's Profits Soar as Memory Chip Demand Booms, Operating Margin Nears 80%. https://smallinsight.com/corporate-analysis/altheogens-eu-early-breast-cancer-approval-boosts-sc/ SmallInsight en 2026-10-28T09:22:28.000Z Altheogen's EU Early Breast Cancer Approval Boosts SC Commercialization Prospects https://smallinsight.com/stock-news/ai-investments-boom-as-big-tech-reshapes-the-employment/ SmallInsight en 2026-10-28T08:59:27.000Z AI Investments Boom as Big Tech Reshapes the Employment Landscape, Downsizing Traditional Workforce https://smallinsight.com/stock-news/will-im-young-woongs-new-venture-rewrite-box-office-history/ SmallInsight en 2026-10-28T08:53:40.000Z Will Im Young-Woong's New Venture Rewrite Box Office History After $100 Million Success? https://smallinsight.com/corporate-analysis/hanall-biopharma-aims-for-2028-graves-disease-treatment-launch/ SmallInsight en 2026-10-28T08:53:40.000Z HanAll Biopharma Aims for 2028 Graves' Disease Treatment Launch with Aimereprobat https://smallinsight.com/market-briefing/ai-stocks-turn-the-tables-buying-switch-flips-back-on/ SmallInsight en 2026-10-28T06:53:59.000Z [Seoul Pre-Market Brief] AI Stocks Turn the Tables, Buying Switch Flips Back On https://smallinsight.com/market-briefing/nasdaq-soars-118-on-semiconductor-strength-boeing-plunges-1069/ SmallInsight en 2026-10-28T06:19:25.000Z Nasdaq Soars 1.18% on Semiconductor Strength; Boeing Plunges 10.69% https://smallinsight.com/market-briefing/october-27th-a-bleak-day-as-antoic-bleeds-under-heavy-selling/ SmallInsight en 2026-10-27T15:15:24.000Z [Seoul Market Wrap] October 27th: A Bleak Day as Antoic Bleeds Under Heavy Selling https://smallinsight.com/corporate-analysis/aimed-bios-adc-leads-the-way-with-first-dosing-set-to-receive/ SmallInsight en 2026-10-27T14:34:59.000Z Aimed Bio's ADC Leads the Way with First Dosing, Set to Receive Subsequent Milestone Payments from Boehringer https://smallinsight.com/corporate-analysis/hd-modern-marine-solutions-suffers-relentless-selloff-analysts/ SmallInsight en 2026-10-27T14:23:04.000Z HD Modern Marine Solutions Suffers Relentless Selloff, Analysts Slash Price Targets https://smallinsight.com/stock-news/will-jeon-do-yeon-knock-on-the-oscar-door-americas-eyes-on/ SmallInsight en 2026-10-27T11:38:17.000Z Will Jeon Do-yeon Knock on the Oscar Door? America's Eyes on 'Possible Love' https://smallinsight.com/corporate-analysis/hlbs-rivoceranib-delivers-118-month-pfs-in-rare-cancer-prepares/ SmallInsight en 2026-10-27T10:38:00.000Z [ESMO 2026 Analysis] HLB's Rivoceranib Delivers 11.8-Month PFS in Rare Cancer; Prepares for U.S. Launch of Lifiting https://smallinsight.com/corporate-analysis/dae-woong-pharm-and-dnc-esthetics-unveiling-the-secrets-to/ SmallInsight en 2026-10-27T08:49:09.000Z Dae Woong Pharm and DNC Esthetics: Unveiling the Secrets to Comprehensive Treatment Strategies for Skin Rejuvenation and Facial Contouring https://smallinsight.com/editors-pick/antropics-historic-ipo-wall-street-joins-forces-shaking-up-the/ SmallInsight en 2026-10-27T08:30:28.000Z Antropic's Historic IPO: Wall Street Joins Forces, Shaking Up the AI Semiconductor Landscape https://smallinsight.com/corporate-analysis/hanall-biopharmas-vatocliumab-receives-chinese-approval-leading/ SmallInsight en 2026-10-27T08:06:59.000Z Hanall Biopharma's Vatocliumab Receives Chinese Approval, Leading to Global Phase III Trials for Next-Gen Antibodies https://smallinsight.com/corporate-analysis/abblifes-trio-of-pipeline-drugs-a-mixed-bag-of-approval-hurdles/ SmallInsight en 2026-10-26T15:50:07.000Z ABBLife's Trio of Pipeline Drugs: A Mixed Bag of Approval Hurdles and Phase 3 Preparations https://smallinsight.com/stock-news/ai-semiconductor-demand-remains-robust-but-growing-concerns-over/ SmallInsight en 2026-10-26T15:40:01.000Z AI Semiconductor Demand Remains Robust, but Growing Concerns Over Funding Pressures